Select Language
CANX OFFERING
Why Invest in CanX CBD
- Global Hemp CBD Market Projected to Surpass $22 Billion USD by 2022
- Europe CBD Market $500 Million USD and Estimated to hit $1.7 Billion USD by 2023
- CanX Well-Positioned as a Profit Leader in the CBD Industry
- Minimal Compliance Overhead – Industrial Hemp < 0.2%THC
- Tight Share Structure with 42.5M Shares Outstanding and 40% Insider Ownership
- IPO Scheduled for Q2/2020
CanX Team
Phillip Fuhrmann
CEO and President
German Citizen- International Law & Business Management. Track record in Corporate Structuring, Business Development and raising capital for Technology, Cannabis, and CBD businesses. Extensive experience in International Compliance and navigating legislative frameworks in the Hemp industry.
Mathew Chadwick
Head of Cultivation&Processing
Over 15 years experience as a MMAR Licensed Grower, specializing in isolation and distillation. Strong track record of delivering superior results on complex, large scope projects. Consultant to a variety of producers focused on process optimization, and extraction techniques.
Iulian Bogatu
General Manager
Manages the day-to-day operations alongside the CEO. Extensive experience in Supply Chain Management and Business Development. Logistics specialist who has manages thousands of clients across the world and delivered significant cost savings.
Constantin Olarasu
Technical Director
Extensive large scale production facilities experience. Agricultural Engineer with numerous years overseeing production and managing a large team of professionals. Focused on continuously increasing production efficiency.
Greg Hall
Director
40 years experience in Venture Capital & Corporate Finance. Former positions: Founding Partner & Director Haywood Securities; VP, Canaccord Genuity; Director & Chairman Audit Committee, SilverCorp Metals (NYSE); Current executive positions with Water Street Assets,Silver Elephant Mining (TSX), Incubara Capital.
What is CBD
Derived from Industrial Hemp
- CBD is one of +85 beneficial compounds in Hemp
- Cannabis Sativa-L <0.2% THC - not psychoactive
- > 25,000 different uses from Oil to Fiber
- CBD shown to mitigate a number of ailments
Health Benefits of CBD
Europe: An Underserved Market
- Most Countries in Europe Already Permit Hemp-Derived Products
- The European Market for CBD is Booming and is Predicted to Grow by 400% in the Next 4 Years.*
- In Germany Alone (Top-three CBD market in Europe), 2018 CBD market was ~$200 Million USD**
- Significant Near-Term Revenue & Branding Opportunity in the CBD Space**
EU - The Right Place at the Right Time
*Grand View Research
**Canaccord Genuity
Why Romania is the Perfect Place
- Top Grower
Romania was one of the top three hemp growers in the world for decades (along with former USSR and Yugoslavia)
- Cost-Effective & Highly Skilled Labour
Access to agriculture and extraction workforce at attractive rates
- EU Member & Globally-compliant Legislation
Strictest THC content (0.2%) regulation clears product for international export
- Ease of Expansion to other EU countries
What Makes CanX Different
EU GMP Certification
- One of few Canadian companies in the industry to receive the EU GMP certification.
- Allowing future fulfilments for international supply agreements.
Flexible Lean Business Model
- Different revenue streams can be adjusted quickly to changing market demands.
In Production
- First Mover Advantage in Europe as only a few dozen companies actually have operations up and running.
Highest Capacity
- One of the Largest and Scalable Extraction Centers in the EU.
Extraction Ready Biomass
- 220,000 lbs. biomass in storage - ready for extraction to generate revenue in an underserved market.
CanX Versus Peers
* Market Cap as at March 11, 2020
** Annualized Sales based on latest Quarterly Financials
*** Projected
Flexible Operating Model
Operations
- Fully Built-out 33,000 Sq. Ft. Extraction Facility In Romania
- Capacity to Process 6,600 lbs. of Biomass per 8-hour shift
- EU GMP* / HACCP**/ ISO 22000 Certification
- Offtake Arrangements/ LOIs/ JVs
- Production & Extraction Underway & Fully Licensed
Technology
- Ethanol-based Extraction effectively captures Cannabinoids (CBD, THC, CBC CBN, CBG) and Terpenes from Biomass
- FDA-approved Solvent, and the most efficient for processing Cannabinoids for bulk-processing facilities
- Wiped and Falling Film post processing creates efficiencies in recovery and gentle product refinement / distillation
- Isolation – Production of 99% pure pharmaceutical grade CBD
- THC Remediation via Chromatography (Broad Spectrum Products/ THC free Oils and derivatives)
- In house formulation experience to create products with custom cannabinoid profiles CBD, CBN, CBC, CBG…
Revenue and Profitability Forecast
Low Opex & Raw Material Cost Coupled with Strong Expected Market Growth will Propel Profit
Timeline
- Finalized biomass offtakes of 1,100 acres with 6 farming groups
- Planted 9 EU approved hemp varieties
- Closed special warrant financing of $4.75M CAD
- Successfully harvested and dried 220,000 lbs. of extraction ready biomass
- Signed lease on 33,000sq. Ft. facility
- Ordered Ethanol extraction equipment started EU GMP / HACCP certification process
- Leasehold improvements including preparing site for equipment installation/ commissioning
- All special warrants converted to common stock
- Start installing extraction equipment
- Complete installation of extraction equipment
- Commencement of CBD oil production/ Toll Processing
- Receive EU GMP / HACCP Certification
- Finalize necessary permits - DSV DSP
Consistent Execution Since Inception
- Public listing on Canadian Securities Exchange (CSE)
- Expand Romanian team to include formulations and in house GMP expert
- Initial Offtake and Distribution Agreements for CBD Oils & Derivatives
- Exploring Expansion into Additional EU Countries
- Creating additional extraction footprints in future hemp cultivation countries in EU
- Scalable model for toll processing and to optimize production and distribution
- Additional Product Refinement, Bio-Availability, time-release/ nano encapsulation
- Launch CanX Proprietary CBD Product Line
- Distribution Partnership with Pharmaceutical / Oncology Companies
Ramping Up Operations and Expanding Across Europe
Ownership Structure & Valuation
Planned IPO Q2/2020 & raising $1,200,000 CAD ($825,000 USD) for legal compliance and sales/marketing OVER 30% DISCOUNT TO CONSERVATIVE CASH FLOW VALUATION